Sirona Biochem Corp V.SBM

Alternate Symbol(s): SRBCF

Healthcare Biotechnology

Sirona Biochem Corp. is a cosmetic ingredient and drug discovery company with a proprietary technology platform developed at its laboratory facility in France with a specialization in the stabilization of carbohydrate molecules. The Company is exploring the areas of diabetes, dyschromia, anti-aging, anti-cellulite and antiviral therapies and relies on a business model of licensing patents to large organizations in return for up-front and milestone payments as well as royalties. Its two most advanced programs are the cosmetic skin lightener and diabetes drug. The Company's TFC-1067 is for the treatment of Dyschromia (Dark spots on the skin). GlycoProteMim is a novel anti-aging compound. GlycoProteMim is based on the naturally occurring glycoproteins found in Antarctic fish, known to protect them against environmental stressors. It is focused on three current antiviral categories: Neuraminidase Inhibitors, Nucleoside Analogs and Iminosugars. Its wholly owned subsidiary is TFChem S.A.R.L.

TSXV:SBM - Post by User

Sirona Biochem Corp > Risk to reward

<< Previous

Bullboard Posts

Next >>

Comment by biorunon Jun 30, 2022 4:14pm

169 Views

Post# 34794966

RE:Risk to reward

Agree. And we will also have 2 other potential deals on the horizon, in massive markets.

The company mentioned to me in response to a question that working with Abbvie has been a completely professional experience. The real McCoy.

Sirona has a reputation now of being able to deal very effectively with a Top 5 pharma. It can do it, and do it again and again. Others are certainly paying attention, fact.

The 2022-23 years is going to be a significant one, in my humble opinion.

<< Previous

Bullboard Posts

Next >>

Changing Europe’s dependency on HREE from China